Overview

* CytoSorbents Q3 2025 revenue rose 10% yr/yr to $9.5 mln, missing analyst expectations

* Adjusted EPS for Q3 2025 beats analyst expectations

* Company implements workforce reduction to accelerate cash-flow breakeven to Q1 2026

Outlook

* CytoSorbents expects cash-flow breakeven by Q1 2026

* Company anticipates FDA decision on DrugSorb-ATR by mid-2026

Result Drivers

* DISTRIBUTOR SALES - Record sales in distributor territories and strong direct sales outside Germany drove revenue growth

* COST REDUCTION - Workforce and cost reduction program implemented to accelerate cash-flow breakeven to Q1 2026

* CREDIT AGREEMENT - Amended credit agreement with Avenue Capital Group strengthens balance sheet with $2.5 mln additional cash

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $9.49 $10 mln

Revenue mln (3

Analysts

)

Q3 Beat -$0.04 -$0.05

Adjusted (3

EPS Analysts

)

Q3 EPS -$0.05

Q3 70.00%

Product

Gross

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Cytosorbents Corp ( CTSO ) is $4.00, about 84% above its November 12 closing price of $0.64

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)